WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.

Biotechnology

Life Sciences

Pharmaceutical

WaveBreak

Bart Henderson

Dawn Adams

Joe Wilson

David Witter

Bochong Li

The Scientific Research Team at WaveBreak is responsible for investigating and characterizing the fleeting protein intermediates central to neurodegenerative disease pathways. They leverage WaveBreak's unique drug discovery platform to develop small-molecule therapeutics that target these transient oligomers, aiming to interrupt their molecular mechanisms. The team focuses on translating their findings into novel treatments for Parkinson's disease, Lewy body dementia, Alzheimer's disease, and ALS.

Scientific Research Team

Leadership Team

Scientific Research Team

About

Team members

Other teams at WaveBreak

Leadership Team